AVEO Pharmaceuticals Inc. appointed John Johnson as a director.
Johnson is the chairman of Strongbridge Biopharma plc and has previously served as chairman of Tranzyme Pharma Inc. and as chairman, president and CEO of Dendreon Corp. and as CEO and a board member of Savient Pharmaceuticals Inc.
In addition, Johnson has held commercial and executive management roles at global corporations that have a focus on oncology, including Johnson & Johnson, Eli Lilly and Co. and Pfizer Inc.
